On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.
23 hours ago | Egyptian Streets
Health insurance companies are no longer allowed to turn away patients because of their pre-existing conditions or charge them more because of those conditions. But some health policy experts say insurers may be doing so in a more subtle way: by forcing people with a variety of illnesses — including Parkinson’s disease, diabetes and epilepsy — to pay more for their drugs.
18 September 2014 | New York Times
Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.
17 September 2014 | Infojustice
Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.
17 September 2014 | I-MAK
more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.
16 September 2014 | Pharmalot
Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.
15 September 2014 | Reuters
Certain key population groups are more vulnerable to HIV infection and have poorer access to services for testing, counselling, treatment and care. These include people who inject drugs, men who have sex with men, sex workers, migrants, prisoners and and transgender people. Thirteen of 28 European countries (46%) have reported that some of their laws, regulations or policies presented obstacles to effective HIV prevention, treatment and care, and support for key populations and other vulnerable subpopulations.
10 September 2014 | WHO
Southern states now have the highest rates of new HIV diagnoses, the largest percentage of people living with the disease, and the most people dying from it, according to Rainey Campbell, executive director of the Southern AIDS Coalition. A new report from the Pew Charitable Trusts makes clearer than ever just how mean-spirited and morally bankrupt the decision of state lawmakers and Governor McCrory to turn down federally-funded Medicaid coverage for hundreds of thousands of low-income North Carolinians is turning out to be.
10 September 2014 | NC Policy Watch
The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).
10 September 2014 | Allafrica.com
Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.
09 September 2014 | Bloomberg